---
title: "Stifel Nicolaus Keeps Their Buy Rating on Crescent Biopharma (CBIO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284860023.md"
description: "Stifel Nicolaus analyst Stephen Willey has reaffirmed a Buy rating on Crescent Biopharma (CBIO) with a price target of $30.00. Willey, who specializes in the Healthcare sector, has an average return of 8.8% and a 43.00% success rate on his stock recommendations. The consensus among analysts for Crescent Biopharma is a Strong Buy, with a price target consensus of $29.50."
datetime: "2026-05-01T02:25:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284860023.md)
  - [en](https://longbridge.com/en/news/284860023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284860023.md)
---

# Stifel Nicolaus Keeps Their Buy Rating on Crescent Biopharma (CBIO)

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Crescent Biopharma yesterday and set a price target of $30.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Incyte, and Insmed. According to TipRanks, Willey has an average return of 8.8% and a 43.00% success rate on recommended stocks.

Crescent Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $29.50.

### Related Stocks

- [CBIO.US](https://longbridge.com/en/quote/CBIO.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Crescita Reports First Quarter 2026 Results | CRRTF Stock News](https://longbridge.com/en/news/285933254.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286678740.md)